|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2100050306 |
|
最近更新日期: Date of Last Refreshed on: |
2022-03-28 16:35:21 |
|
注册时间: Date of Registration: |
2021-08-26 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
多巴胺用于预防老年非心脏手术患者右美托咪定复合全麻时诱导期低血压的有效性和安全性研究 |
|
Public title: |
Efficacy and safety of dopamine infusion for prevention of hypotension after induction of general anesthesia combined with dexmedetomidine in elderly patients undergoing noncardiac surgery |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
多巴胺用于预防老年非心脏手术患者右美托咪定复合全麻时诱导期低血压的有效性和安全性研究 |
|
Scientific title: |
Efficacy and safety of dopamine infusion for prevention of hypotension after induction of general anesthesia combined with dexmedetomidine in elderly patients undergoing noncardiac surgery |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
田磊 |
研究负责人: |
田磊 |
|
Applicant: |
Tian Lei |
Study leader: |
Tian Lei |
|
申请注册联系人电话: Applicant telephone: |
+86 18882004170 |
研究负责人电话: Study leader's telephone: |
+86 18882004170 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
tlnc1990@163.com |
研究负责人电子邮件: Study leader's E-mail: |
tlnc1990@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
四川省自贡市自流井区尚义灏一支路42号 |
研究负责人通讯地址: |
四川省自贡市自流井区尚义灏一支路42号 |
|
Applicant address: |
42 Shangyihao First Branch Road, Ziliujing District, Zigong, Sichuan |
Study leader's address: |
42 Shangyihao First Branch Road, Ziliujing District, Zigong, Sichuan |
|
申请注册联系人邮政编码: Applicant postcode: |
643000 |
研究负责人邮政编码: Study leader's postcode: |
643000 |
|
申请人所在单位: |
自贡市第一人民医院 |
||
|
Applicant's institution: |
Zigong First People's Hospital |
||
|
研究负责人所在单位: |
自贡市第一人民医院 |
||
|
Affiliation of the Leader: |
Zigong First People's Hospital |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
伦理(研)2021年第21号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
自贡市第一人民医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Zigong First People's Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2021-05-06 00:00:00 |
||
|
伦理委员会联系人: |
临床试验伦理委员会办公室 |
||
|
Contact Name of the ethic committee: |
The Office of the Clinical Trial Ethics Committee |
||
|
伦理委员会联系地址: |
四川省自贡市自流井区尚义灏一支路42号 |
||
|
Contact Address of the ethic committee: |
42 Shangyihao First Branch Road, Ziliujing District, Zigong, Sichuan |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 813 2107682 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
2667360640@qq.com |
|
研究实施负责(组长)单位: |
自贡市第一人民医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Zigong First People's Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
四川省自贡市自流井区尚义灏一支路42号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
42 Shangyihao First Branch Road, Ziliujing District, Zigong, Sichuan |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自筹 |
||||||||||||||||||||||
|
Source(s) of funding: |
Self-financed |
||||||||||||||||||||||
|
Target disease: |
hypotension |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
本研究的目的是探讨多巴胺用于预防老年患者右美托咪定复合全麻时诱导期低血压的有效性和安全性,为减少诱导期低血压、指导麻醉药物合理配伍提供参考。 |
||||||||||||||||||||||
|
Objectives of Study: |
To evaluate the efficacy and safety of dopamine infusion for prevention of hypotension after induction of general anesthesia combined with dexmedetomidine in elderly patients undergoing noncardiac surgery, and to provide reference for reducing induced hypotension and guiding the rational compatibility of anesthetics. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.年龄65岁以上,性别不限; |
||||||||||||||||||||||
|
Inclusion criteria |
1.65 years or older, no gender limit; |
||||||||||||||||||||||
|
排除标准: |
1.急诊手术; |
||||||||||||||||||||||
|
Exclusion criteria: |
(1) Emergency surgery; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2021-12-01 00:00:00至 To 2022-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2022-02-01 00:00:00 至 To 2022-07-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
采用SPSS软件产生随机数字量表。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Random random are generated using the spss software. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
为保证盲法,药物配制由单独麻醉医生完成,均为生理盐水配制,无色无味,并分别标记A药、B药、C药,该麻醉医生不参与后续研究,诱导时三组均输注相同体积的试验用药。病人和参与研究的麻醉医生均不知道泵注药物种类。事后统计分析由另一位不参与研究的麻醉医生完成。 |
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
公开日期2022.11.31;方式:附件 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Open date: 2022.11.31;way: appendix |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |